Skip to main content
RVMD logo

Revolution Medicines, Inc. (RVMD) Stock: Price, Forecast & Analyst Target

Revolution Medicines, Inc. (RVMD) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $159.43 (-0.24%), as of the Nov 19, 2026 trading session; market cap $34.5B.

Educational signal · not a buy or sell recommendation · How to read this

$159.43 −$0.39 (-0.24%) Market Cap $34.5B

Revolution Medicines, Inc. · RVMD · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): Revolution Medicines is a clinical-stage precision oncology developer focused on therapies for RAS-driven cancers, not a drug seller with an established commercial franchise. Its equity case depends on whether clinical progress can justify rapidly expanding development and manufacturing expenditure before cash consumption erodes the current funding cushion.

Price as of Nov 19, 2026

Key Statistics

23 of 100

MoonshotScore v2 · Revolution Medicines (RVMD)

Weak
Business Quality Poor (17)
Financial Safety Okay (55)
Valuation Rich (38)
Growth Durability Shrinking (3)
Momentum Surging (86)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Surging.

  • EPS beat 1 of the last 8 reports
  • Altman Z 9.33 · Piotroski F 4
  • ROE -93.6% · ROA -32.1% · current ratio 8.36

Holding back: weak fundamentals, soft growth

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RVMD (57 recorded, newest six shown)
RecordedScoreBand
25Weak
25Weak
24Weak
24Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$159.43
Change on the day-0.24%
52-week range$67.86–$224.31
Market capitalisation$34.5B—
Price / earnings (trailing)-25.13
Shares traded on the day2.59M
Beta (volatility vs the S&P 500)1.43

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $54, high $210, latest $159. $210 $54 high $210 Oct 17, 2025 Nov 19, 2026 · $159 $54Oct 17, 2025$59Oct 31, 2025$68Nov 14, 2025$78Nov 28, 2025$79Dec 12, 2025$81Dec 26, 2025$119Jan 9, 2026$118Jan 23, 2026$97Feb 6, 2026$102Feb 20, 2026$98Mar 6, 2026$96Mar 20, 2026$99Apr 2, 2026$149Apr 17, 2026$139May 1, 2026$146May 15, 2026$157May 29, 2026$154Jun 12, 2026$182Jun 26, 2026$187Jul 10, 2026$189Jul 24, 2026$205Aug 7, 2026$209Aug 21, 2026$210Sep 4, 2026$191Sep 18, 2026$207Oct 2, 2026$178Oct 16, 2026$191Oct 30, 2026$172Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Revolution Medicines (RVMD): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Neutral
Valuation Weak
Growth Durability Negative
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Moderate
ROE Negative
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Revolution Medicines (RVMD), and what does it report?

Short answer · as of

The company develops compounds that inhibit active RAS variants or related signaling proteins implicated in solid tumors.

Its portfolio includes direct active RAS inhibitors as well as programs aimed at associated pathways, with Sanofi participating in a collaboration around an allied inhibitor program.

Reported revenue has disappeared after earlier collaboration revenue, leaving research, overhead, operating losses and cash use as the meaningful accounting outputs. The income statement therefore measures the cost of advancing and preparing the pipeline rather than customer demand for marketed medicines.

2 · Latest results

What do the latest results show for Revolution Medicines (RVMD)?

The latest period continued a stark progression: revenue remained absent while research expense, overhead, operating loss and net loss all increased. Operating cash consumption accelerated even more sharply, and reported losses have repeatedly been worse than market estimates.

Management says planned spending will rise largely because Revolution Medicines is accelerating manufacturing for daraxonrasib and zoldonrasib across clinical and potential commercial supply. That explains part of the prospective cost pressure, but inventory preparation for possible demand is not evidence that product sales have begun.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$198M-$407M-$1.90 (diluted)
Q2 FY2026$0-$644M-$3.06 (diluted)
Q1 FY2026$0-$454M-$2.29 (diluted)
Q4 FY2025$0-$365M-$1.92 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Revolution Medicines (RVMD)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash and investments comfortably exceed debt and total liabilities, while the cash balance increased sharply in the latest period. At the recent annualized usage rate, the estimated runway extends well beyond the near term, reducing immediate financing pressure.

The protection is finite because operating cash consumption and losses are accelerating as the development organization scales. Market value also stands far above net cash, so adverse clinical evidence or prolonged commercialization delays could damage the valuation long before liquidity becomes scarce.

Data-derived red flags

  • Negative return on equity (-93.6%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at Revolution Medicines (RVMD)?

Short answer · as of

Current published price targets run low $179.00 · high $350.00 · consensus $257.59 · median $260.00 against a quoted price of $159.43 (as of Nov 19, 2026).

Research expense, overhead and operating cash consumption are the clearest near-term gauges. The scheduled earnings release should reveal whether spending continues to accelerate as manufacturing expands and whether reported revenue reappears after its prolonged absence.

Long-range revenue forecasts span a wide range, reflecting sharply different commercialization assumptions. Recent filings also identify material agreements after the latest periodic report, making their effect on future cash and liabilities another point to reconcile when fuller financial detail arrives.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Revolution Medicines compare with its peers?

Short answer

Revolution Medicines's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

A revenue-producing oncology company is the wrong economic comparison: Revolution Medicines is still converting capital into clinical programs, manufacturing capacity and evidence. Current financial performance is consequently defined by research expenditure and cash consumption rather than product margins or prescription volume.

Its distinguishing feature is a portfolio built around RAS-driven cancers, combining direct active RAS inhibitors with programs aimed at related signaling pathways and a Sanofi collaboration. Candidate progress and the ability to translate that scientific concentration into commercial demand matter more than conventional revenue comparisons.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Named competitor$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$942.04 Nov 19, 2026$59.2B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Same industry, near in market value$68.67 Nov 18, 2026$39.5B73 5-pillar Nov 18, 2026
Genmab A/S (GMAB) Same industry, near in market value$50.97 Nov 18, 2026$31.4B72 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
Moderna, Inc. (MRNA) Named competitor$196.79 Nov 18, 2026$79.6B31 5-pillar Nov 18, 2026
Revolution Medicines (RVMD) — this page$159.43$34.5B23

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$179.00 – $350.00
Consensus target
$257.59
Median target
$260.00

Consensus record · Captured .

Measured against a quoted price of $159.43 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
185
Identified insiders
14
Purchases
0
Sales
122
Other transactions
63

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RVMD in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20262.00%$89.55MAdded +9.2% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Revolution Medicines (RVMD)?

Read these with our analysis →

Revolution Medicines Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Why does Revolution Medicines report no revenue while developing RAS drugs?

The company remains in clinical development, so advancing its oncology pipeline currently generates research expense rather than product sales. Earlier reported revenue came from collaboration activity and has since disappeared.

What does daraxonrasib manufacturing mean for Revolution Medicines?

Management is accelerating manufacturing for clinical supply and potential commercial demand scenarios, which is expected to increase spending. The buildout signals preparation, while commercial demand still depends on successful development.

How dependent is Revolution Medicines on active RAS inhibitors?

Active RAS biology anchors the portfolio, including compounds aimed directly at active variants and programs targeting related signaling pathways. This concentration makes clinical evidence from the RAS franchise especially important to the business.

Can Revolution Medicines fund daraxonrasib and zoldonrasib development?

Current liquidity provides meaningful funding capacity and exceeds debt by a wide margin, with the estimated runway extending beyond the near term. Accelerating cash consumption means that cushion should be judged against the expanding research and manufacturing program, not viewed as permanent.

What is the RVMD stock price today?

The last price recorded for Revolution Medicines, Inc. (RVMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RVMD price target?

The analyst consensus price target for Revolution Medicines, Inc. (RVMD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Sector / industry (provider taxonomy); Business description; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is Revolution Medicines (RVMD), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 2. What do the latest results show for Revolution Medicines (RVMD)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Revolution Medicines (RVMD)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Cash against market value; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • 4. What should you watch next at Revolution Medicines (RVMD)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts; Recent SEC filings; Most recent periodic reports
  • 5. How does Revolution Medicines compare with its peers?: Sector / industry (provider taxonomy); Business description; Annual revenue and net result (USD millions); Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • FAQ: Why does Revolution Medicines report no revenue while developing RAS drugs?: Business description; Annual revenue and net result (USD millions); Revenue by segment; Quarterly income statement (USD thousands)
  • FAQ: What does daraxonrasib manufacturing mean for Revolution Medicines?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: How dependent is Revolution Medicines on active RAS inhibitors?: Business description; Management outlook — dated call excerpts
  • FAQ: Can Revolution Medicines fund daraxonrasib and zoldonrasib development?: Cash, investments and debt; Cash and investment components; Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold RVMD

Funds in our ETF coverage that list RVMD among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Genomics Immunology and Healthcare ETF (IDNA)4.35%
State Street SPDR S&P Biotech ETF (XBI)1.59%